Stocks to BUY, SELL or HOLD Today, March 27: Brokerage firms such as Motilal Oswal, Morgan Stanley, Elara Capital and others have released their latest stock recommendations for March 27, highlighting key BUY, SELL, and HOLD calls across major Indian companies.
Stocks like ICICI Prudential AMC, Mankind Pharma, and SBI have received positive outlooks, while Biocon faces a cautious stance. With updated target prices and growth expectations, these insights offer investors a snapshot of market sentiment and potential opportunities in sectors such as banking, pharmaceuticals, and technology.
Here’s the list of stocks to BUY, SELL or HOLD in today’s trading session:
Mankind Pharma Share Price Target 2026
Morgan Stanley has initiated ‘Overweight’ coverage on Mankind Pharma with a target price of Rs 2,500, backed by expectations of a healthy revenue CAGR of around 11 per cent over FY26–FY28.
Torrent Pharma Share Price Target 2026
Morgan Stanley has initiated coverage on Torrent Pharmaceuticals with an Equal Weight rating and a target price of Rs 4,580.
United Spirits Share Price Target 2026
Elara Capital has upgraded United Spirits to Buy, raising its target price to Rs 1,650 from Rs 1,500. The RCB franchise stake is valued at around Rs 166 billion, providing meaningful upside potential alongside core business growth.
Azad Engineering Share Price Target 2026
Goldman Sachs has maintained its Buy rating on Azad Engineering with a target price of Rs 2,200. This is supported by a contract signed with Mitsubishi Heavy Industries.
L&T Technology Services Share Price Target 2026
Morgan Stanley has maintained an Equal Weight rating on L&T Technology Services (LTTS) with an unchanged target price of Rs 4,420.
Infosys Share Price Target 2026
Morgan Stanley has maintained an Equal Weight rating on Infosys with an unchanged target price of Rs 1,760, while noting the acquisitions of Optimum Healthcare IT and Stratus.
SBI Share Price Target 2026
Antique has maintained its Buy rating on State Bank of India (SBI) while reducing the target price to Rs 1,200, a 1 per cent cut from the previous target.
Biocon Share Price Target 2026
Citi has resumed coverage on Biocon with a Sell rating and a target price of Rs 360 per share, implying a 5 per cent downside from the current market price.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions.)
